Activation of PPARγ and δ by dietary punicic acid ameliorates intestinal inflammation in mice

Josep Bassaganya-Riera1*, Margaret DiGuardo2, Montse Climent1, Cristina Vives1, Adria Carbo1, Zeina E. Jouni3, Alexandra W. C. Einerhand4, Marianne O’Shea3 and Raquel Hontecillas1

1Laboratory of Nutritional Immunology and Molecular Nutrition, Virginia Biotechnology Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
2Nutrition Therapeutics, Inc., Blacksburg, VA 24061, USA
3Mead Johnson Nutrition, Evansville, IN 47721, USA
4Lipid Nutrition BV, Channahon, IL 60410, USA

(Received 11 May 2010 – Revised 13 January 2011 – Accepted 18 January 2011 – First published online 31 May 2011)

Abstract

The goal of the present study was to elucidate the mechanisms of immunoregulation by which dietary punicic acid (PUA) prevents or ameliorates experimental inflammatory bowel disease (IBD). The expression of PPARγ and δ, their responsive genes and pro-inflammatory cytokines was assayed in the colonic mucosa. Immune cell-specific PPAR expression was measured in C57Bl/6 mice by real-time PCR. The prophylactic efficacy of PUA was examined in an IL-10null model of IBD. The effect of PUA on the regulatory T-cell (Treg) compartment was also examined in mice with experimental IBD. PUA ameliorated spontaneous pan-enteritis in IL-10null mice and DSS colitis, up-regulated Foxp3 expression in Treg and suppressed TNF-α, but the loss of functional PPARγ or δ impaired these anti-inflammatory effects. At the cellular level, the macrophage-specific deletion of PPARγ caused a complete abrogation of the protective effect of PUA, whereas the deletion of PPARδ or intestinal epithelial cell-specific PPARγ decreased its anti-inflammatory efficacy. We provide in vivo molecular evidence demonstrating that PUA ameliorates experimental IBD by regulating macrophage and T-cell function through PPARγ- and δ-dependent mechanisms.

Key words: Inflammatory bowel disease; PPAR; Punicic acid

Inflammatory bowel disease (IBD) is a widespread and debilitating illness characterised by the destruction of the gut mucosa by the mucosal immune system(1). Activation of PPARγ has shown efficacy in the prevention or amelioration of experimental IBD(2–4). Results of a recent clinical study in ulcerative colitis patients demonstrate that rosiglitazone (Avandia™, GlaxoSmithKline, London, UK), an agonist of PPARγ and a Food and Drug Administration-approved drug for treating type 2 diabetes, is also efficacious in the treatment of mild-to-moderate ulcerative colitis(5). In spite of its efficacy, rosiglitazone is unlikely to be adopted or no adverse side effects. A safer alternative to rosiglitazone in particular, or the thiazolidinedione class of anti-diabetic drugs in general (i.e. rosiglitazone, ciglitazone, troglitazone and pioglitazone), is conjugated linoleic acid (CLA), a naturally occurring fatty acid that ameliorates IBD through a PPARγ-dependent mechanism(5,8,9). The efficacy of CLA against experimental IBD heightened our interest in discovering naturally occurring, orally active agonists of PPAR. In this regard, conjugated linolenic acids such as punicic acid (PUA), catalpic acid and eleostearic acid have demonstrated some promising effects as dual or pan-agonists of PPAR that exert therapeutic and prophylactic actions against IBD with limited or no adverse side effects.

Abbreviations: cDNA, complementary DNA; CLA, conjugated linoleic acid; DK, double knockout; DSS, dextran sodium sulphate; IBD, inflammatory bowel disease; IEC, intestinal epithelial cell; PUA, punicic acid.

* Corresponding author: Dr J. Bassaganya-Riera, fax +1 540 231 2606, email jbassaga@vt.edu
As with thiazolidinedione, PUA ameliorates glucose tolerance and obesity-related inflammation in animal models of obesity and type 2 diabetes by acting as dual PPARs and γ agonists\(^{11,17,18}\) with no adverse side effects detected in toxicological studies\(^{19}\). At the gastrointestinal tract, PUA inhibits TNF-α-induced neutrophil hyperactivation, protects from experimental colitis\(^{20}\), and ameliorates inflammation-induced colorectal cancer\(^{21}\). While some progress has been made in characterising some of the health effects of PUA, its underlying mechanisms of action are incompletely understood. The present study aims to elucidate the underlying mechanisms by which PUA ameliorates experimental IBD. Particularly, we investigate the role of PPAR as putative molecular targets for the prevention of IBD by PUA.

### Experimental methods

#### Animal procedures

C57BL/6j wild-type mice and IL-10\(^{−/−}\) mice were purchased from the Jackson Laboratories (Bar Harbor, ME, USA). Tissue-specific PPAR\(\gamma\) null mice were generated as described previously\(^{5,22-25}\). The tail and colonic genotypes of mice were determined by PCR analysis as described previously\(^{5,24}\). PPAR\(\gamma\) fl/fl; mouse mammary tumour virus (MMTV)-Cre\(^{+}\); IL-10\(^{−/−}\) double knockout (DK) mice were generated by breeding IL-10\(^{−/−}\) mice and tissue-specific PPAR\(\gamma\) null mice expressing the MMTV-Cre recombinase in epithelial and haematopoietic cells. PPAR\(\delta\) null mice were backcrossed nine times to a C57BL/6j background and genotyped as described previously\(^{25}\). We also utilised Villin-Cre mice lacking PPAR\(\gamma\) in intestinal epithelial cells (IEC)\(^{20,27}\), CD4-Cre mice lacking PPAR\(\gamma\) in T-cells\(^{28}\) and Lysozyme M-Cre mice lacking PPAR\(\gamma\) in macrophages and neutrophils\(^{29,30}\). All mouse strains were bred under a C57BL/6j background. While we attempted to generate PPAR\(\gamma\); IL-10\(^{−/−}\) DK mice, we were not successful due to increased embryonic mortality of mice lacking both PPAR\(\delta\) and IL-10. Mice were maintained at the experimental facilities at Virginia Polytechnic Institute and State University. All experimental protocols were approved by the Institutional Animal Care and Use Committee.

#### Dietary treatments and development of experimental colitis

Mice were fed purified diets for 6 weeks that represented a modification of the AIN-93G diet (Table 1) commonly used for the growth, pregnancy and lactational phases of mice\(^{31}\). The optimal doses of PUA included in these diets were the result of time course and dose titration studies designed to elucidate the optimal anti-inflammatory efficacy of PUA performed previously (data not shown). Diets were prepared on a weekly basis, and feed was replaced on a daily basis to minimise fatty acid oxidation. Stock fatty acid solutions, e.g. pomegranate seed oil, were nitrogen-purged every time that the bottles were opened. The fatty acid profile of pomegranate seed oil was determined by NMR as described previously\(^{122}\) and shown to contain over 71% PUA. For studies using IL-10\(^{−/−}\) mice, breeder pairs were maintained in specific pathogen-free conditions, and pups were transferred into a conventional environment at weaning (21 d of age) to facilitate a greater microbial exposure and the development of experimental IBD. The treatment groups were (1) wild-type mice (negative control for colitis; n = 12), (2) IL-10\(^{−/−}\) mice with severe colitis at the start of the experiment (n = 20) to investigate therapeutic efficacy, (3) IL-10\(^{−/−}\) mice that have not developed colitis at the start of the experiment (n = 20) to investigate prophylactic efficacy and (4) PPAR\(\gamma\) fl/fl; MMTV-Cre\(^{+}\); IL-10\(^{−/−}\) DK mice (n = 20) to investigate the role of PPAR\(\gamma\) in mediating the anti-inflammatory effect of PUA in the IL-10 model of spontaneous pan-enteritis. In the dextran sodium sulphate (DSS) studies, we used the following mouse genotypes: wild-type; whole-body PPAR\(\delta\) null; IEC-specific PPAR\(\gamma\) null (Villin-Cre); macrophage-specific PPAR\(\gamma\) null (Lysozyme M-Cre). Experimental diets provided a dose of PUA equivalent to 45–80 mg PUA/d per mouse. Subsequent studies used the DSS model of experimental IBD by inducing colitis by challenging mice with 2.5% DSS, 36,000–44,000 molecular weight (ICN Biomedicals, Aurora, OH, USA) in the drinking-water for 7 d as described previously\(^{5}\).

### Assessment of colitis

Mice were weighed on a daily basis and examined for clinical signs of disease associated with colitis (i.e. perianal soiling, rectal bleeding, rectal prolapses, diarrhoea and piloeruption).

### Table 1. Composition of the diets*

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Control diet</th>
<th>PUA-supplemented diet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Casein</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>l-Cystine</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Maize starch</td>
<td>397-486</td>
<td>397-486</td>
</tr>
<tr>
<td>Maltodextrin</td>
<td>132</td>
<td>132</td>
</tr>
<tr>
<td>Sucrose</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Mineral mix (AIN-93)†</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>Vitamin mix (AIN-93)†</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>2-5</td>
<td>2-5</td>
</tr>
<tr>
<td>tert-Butylhydroquinone§</td>
<td>0-014</td>
<td>0-014</td>
</tr>
<tr>
<td>Soyabean oil</td>
<td>60</td>
<td>60</td>
</tr>
<tr>
<td>Linoleic acid</td>
<td>10</td>
<td>–</td>
</tr>
<tr>
<td>Pomegranate oil</td>
<td>–</td>
<td>10</td>
</tr>
</tbody>
</table>

PUA, punicic acid.

* Provides approximately 7% fat and 0.02 total cholesterol, and obtains 14.5% of energy from fat. All dietary ingredients were purchased from Harlan Teklad (Madison, WI, USA), with the exception of pomegranate seed oil that was provided by Lipid Nutrition BV (Wormerveer, The Netherlands).

† Supplied per kg of diet: calcium carbonate, 357 g; potassium phosphate monobasic, 196 g; potassium citrate, 70-78 g; NaCl, 74 g; potassium sulphate, 46-6 g; magnesium oxide, 24-3 g; ferric citrate, 6-06 g; zinc carbonate, 1-65 g; manganese carbonate, 0.63 g; cupric carbonate, 0.31 g; potassium iodate, 0.01 g; sodium selenate, 0.01025 g; ammonium para-lysozyme, 0.00795 g; sodium metasilicate, 1-45 g; chromium potassium sulphate, 0.275 g; lithium chloride, 0.0174 g; boron acid, 0.0815 g; sodium fluoride, 0.0635 g; nickel carbonate, hydroxide, tetrahydrate, 0.0318 g; ammonium vanadate, 0.0066 g; sucrose, 220-716 g.

§ Supplied per kg of diet: nicotinic acid, 3 g; calcium pantothenate, 1-6 g; pyridoxine hydrochloride, 0-7 g; thiamine hydrochloride, 0-6 g; riboflavin, 0-6 g; folic acid, 0.2 g; biotin, 0.02 g; vitamin B12 (0.1% in mannitol), 2-5 g; dl-α-tocopherol acetate (333-5 mg/g), 15 g; vitamin A palmitate (150,000 μg retinol/g), 0.8 g; vitamin D3 (cholecalciferol, 12,500 μg/g), 0.2 g; vitamin K (phyloquinone), 0.075 g; sucrose, 974-759 g.
by blinded observers. Disease activity indices were calculated using a modification of a previously published compounded clinical score(3,32). Briefly, disease activity index consisted of a scoring for diarrhoea and lethargy (0–3), whereas rectal bleeding consisted of a visual observation of blood in faeces and the perianal area (0–4). Results from preliminary studies demonstrated a high correlation between the results of faecal blood by Hemoccult and visual observations performed by experienced veterinarians. Mice in the DSS study were euthanised by CO2 narcosis followed by secondary thoracotomy on day 7 of the DSS challenge.

**Histopathology**

Segments of the colon (3 cm of the anatomic middle of the colon) were fixed in 10% buffered neutral formalin, later embedded in paraffin, and then sectioned (6 μm) and stained with haematoxylin and eosin for histological examination. Tissue slides were examined as described previously(3,33,34). Briefly, colons were graded with a compounded histological score including the extent of (1) crypt damage, (2) regeneration, (3) metaplasia/hyperplasia, (4) lamina proprial vascular changes, (5) submucosal changes and (6) presence of inflammatory infiltrates. The sections were graded with a range from 0 to 4 for each of the previous categories, and data were analysed as a normalised compounded score. We show the colonic results because the colonic lesions are common in the IL-10−/− and DSS colitis models. The ileal lesions can only be found in the IL-10−/− model but not in the DSS model, which is colon-specific.

**Quantitative real-time RT-PCR from the colon**

Total RNA was isolated from colonic samples using the RNeasy isolation kit (Qiagen, Valencia, CA, USA) to examine the expression of the three PPAR isoforms and PPAR-responsive genes. The PCR primer pairs for the genes of interest were designed based on previously published sequences (GenBank) using the Oligo 6 primer design software (Molecular Biology Insights, Cascade, CO, USA), and real-time RT-PCR was performed as described previously(3,9). Briefly, total RNA was isolated from the whole colon of mice using the RNA isolation MiniKit (Qiagen) according to the manufacturer’s instructions. All RNA samples were checked for quality and quantity on the Agilent 2100 BioAnalyser system (Agilent Technologies, Palo Alto, CA, USA). Total RNA (1 μg) from each sample was used to generate a complementary DNA (cDNA) template using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The total reaction volume was 20 μl. The reaction was incubated in a Tetrad thermocycler.

![Fig. 1. Effect of punicic acid (PUA) on disease activity indices during 42 d. (A) C57BL/6J wild-type mice fed either a control (– – –) diet or a diet supplemented with PUA (1 g/100 g; – – –). (B) IL-10-deficient mice with no signs of disease before day 0 of the study (IL-10−/−). (C) IL-10−/− mice with severe inflammatory bowel disease on day 0 of the study (IL-10−/−). (D) PPARγ fl/fl; MMTV-Cre+; IL-10−/− double knockout mice. * Mean values were significantly different between the treatments (P<0.05, n 10).](image-url)
(MJ Research, Waltham, MA, USA) as follows: 5 min at 25°C, 30 min at 42°C, 5 min at 85°C, hold at 4°C. cDNA products were diluted 1:10 in diethylpyrocarbonate-treated water. Controls were also performed with no RNA template (no template) and omitting the RT enzyme (no RT).

The PCR primer pairs were designed based on previously published sequences (GenBank) using the Oligo 6 primer design software (Molecular Biology Insights). The PCR primer pair sequences, annealing temperatures, accession numbers and PCR product lengths are outlined in Table S1 of the supplementary material (available online at http://www.journals.cambridge.org/bjn.org). PCR was performed on cDNA using Taq DNA Polymerase obtained from Invitrogen (Carlsbad, CA, USA) and using previously described conditions,(9,35) and each gene amplicon was purified using the MinElute PCR Purification kit (Qiagen). The purified amplicon for each gene was quantified on an agarose gel and also with the GeneQuant Pro spectrophotometer (Amersham Biosciences, Piscataway, NJ, USA). These purified amplicons were further used to optimise the real-time PCR conditions and to generate the standard curves in the real-time PCR assay. Primer concentrations and annealing temperatures were optimised for the iCycler iQ System (Bio-Rad) for each set of primers using the system's gradient protocol. PCR efficiencies were maintained at 100% for each primer set during optimisation and also during the real-time PCR of sample cDNA.

**Statistical analyses**

ANOVA was used to determine the statistical significance of the model: main effects of diet, genotype, time, two-way and three-way interactions when time was a factor. ANOVA was performed using the general linear model procedure of Statistical Analysis Software (SAS Institute, Inc., Cary, NC, USA) as described previously. Data were analysed as factorial arrangements of treatments. The statistical model was

\[ Y_{ijk} = \mu + \text{genotype}_i + \text{diet}_j + (\text{genotype} \times \text{diet})_{ij} + \text{error}_{ijk}, \]

where \( \mu \) is the general mean, genotype, is the main effect of the \( i \)th level of the genotypic effect (expression of PPARγ in the immune and epithelial cells), diet, is the main effect of the \( j \)th level of the dietary effect (PUA vs. control), (genotype \times diet)\( _{ij} \) is the interaction effect between genotype and diet, and error \( A \) is the random error. When the model was significant, the analysis was followed by Scheffe's multiple comparison method. Data are expressed as means with their standard errors of the mean. For analysing the results of the disease activity index over time, we used a three-factor repeated-measures ANOVA. For this analysis, in addition to the main effects of diet and genotype and the two-way interaction between diet and genotype (as shown earlier), the model included the main effect of time, the diet \( \times \) time, genotype \( \times \) time interactions and the three-factor interaction (diet \( \times \) genotype \( \times \) time). Statistical significance was assessed at a probability value (\( P<0.05 \)).

**Results**

**Disease activity indices**

No effect of PUA was observed in disease activity indices of wild-type mice (Fig. 1(A)). PUA prevented experimental IBD in IL-10\(^{−/−}\) mice (Fig. 1(B)). Even though there were some favourable numerical differences, PUA did not cure IBD in mice that received it after having developed severe clinical signs such as rectal prolapses (Fig. 1(C)). The deficiency of PPARγ in immune and epithelial cells in PPARγ fl/fl; MMTV-Cre+; IL-10 DK mice abrogated the beneficial effect of PUA in experimental IBD (Fig. 1(D)) even when PUA was administered preventively. Even though we also attempted to generate a line of PPARγ; IL-10 DK, we were unable to produce this line due to embryonic mortality associated with this genotype. Thus, we evaluated the role of PPARγ in PUA-mediated protection from IBD using a model of DSS colitis.

**Intestinal inflammatory lesions**

The architecture of colons recovered from IL-10\(^{−/−}\) P mice administered PUA resembled those of healthy wild-type mice. Specifically, PUA significantly decreased the histological scores, including lymphoplasmacytic infiltration and enlargement of
the colonic mucosa of IL-10\(^{-/-}\) P, but not in IL-10\(^{-/-}\) T, mice or in PPAR\(\gamma\) fl/fl; MMTV-Cre+; IL-10 DK mice (Fig. 2).

**Quantification of colonic gene expression**

Quantitative real-time RT-PCR analyses demonstrated that colonic PPAR\(\delta\) was significantly up-regulated, and the expression of PPAR\(\delta\)-responsive gene angiopoietin-like 4 was numerically increased by PUA (Fig. 3(A) and (B)). No differences were observed in the colonic expression of PPAR\(\alpha\), \(\gamma\) or their responsive genes CD36, FABP4 and stearoyl coenzyme A desaturase 1 (data not shown). PUA suppressed the colonic expression of both TNF-\(\alpha\) and MCP-1 (Fig. 3(C) and (D)). PUA significantly up-regulated the colonic expression of keratinocyte growth factor in comparison with control diet-fed mice (0·01 \(v.\) 0·005, \(P<0·02\)). Keratinocyte growth factor is a growth factor associated with epithelial wound healing.

**Effect of cell-specific deficiency of PPAR\(\gamma\) and \(\delta\) on the ability of punicic acid to prevent or ameliorate dextran sodium sulphate colitis**

PUA protected wild-type mice from experimental IBD, but its beneficial effects in disease activity and colonic lesions were abrogated in PPAR\(\delta\) null mice (Fig. 4) and significantly impaired in IEC-specific (Villin-Cre) (Fig. 5) and macrophage-specific (Lysozyme M-Cre) PPAR\(\gamma\) null mice (Fig. 6), suggesting that PPAR\(\gamma\) and \(\delta\) in immune and epithelial cells are required for PUA-mediated protection from experimental IBD. The highest disease activity was observed in Lysozyme M-Cre mice, regardless of the diet (Fig. 6), indicating that the deficiency of PPAR\(\gamma\) in macrophages is a particularly important contributor to the immunopathogenesis of IBD, as shown previously\(^{(29)}\). Flow cytometric analyses of T-cell subsets in blood and mesenteric lymph nodes (MLN) demonstrated that PUA increased the percentages of regulatory T-cells in the blood of wild-type mice but not in mice lacking PPAR\(\gamma\) or \(\delta\) in immune or epithelial cells (Fig. 7).

**Discussion**

Nutritional influences can target the main components of mucosal homeostasis during IBD and contribute to either attenuating or accentuating the onset of disease\(^{(37,38)}\). Both fatty acid composition of the diet and total amount of dietary fat\(^{(39–41)}\) define the variables of lipid nutrition that influence health and disease. For instance, mixed results are available on the modulation of intestinal inflammation by \(n\)-3 PUFA, although CLA has shown anti-inflammatory efficacy more consistently, primarily by targeting PPAR\(^{(42)}\). At the molecular level, PPAR represent important targets for the actions of...
dietary lipid and major contributors to the maintenance of intestinal homeostasis. In this regard, PPARγ gene therapy enhances PPARγ mRNA expression, resulting in dramatic therapeutic benefits in the DSS colitis model. CLA induced colonic PPARγ expression and provided protection against the disease in a pig model of bacterial-induced colitis, as well as in mouse and pig models of DSS colitis. The present study investigates the possibility of a PPAR-dependent mechanism underlying the anti-inflammatory efficacy of PUA against experimental IBD.

PPARγ and δ are recognised as central inhibitors of intestinal inflammation in DSS colitis. In addition, activation of PPARγ by rosiglitazone ameliorated spontaneous panenteritis caused by the deficiency of IL-10. In the present study, we provide evidence that preventive administration of PUA ameliorated IBD in two mouse models of IBD. However, PUA was not effective in IL-10−/− mice with established severe inflammatory lesions (i.e. rectal prolapses) and PPARγ; IL-10 DK mice. The latter finding suggests that the anti-inflammatory efficacy of PUA depends on the expression of functional PPARγ in immune and epithelial cells. Interestingly, colonic expression of PPARδ and its responsive gene angiopoietin-like 4 was up-regulated in IL-10−/− mice that received PUA preventively. These in vivo findings were in line with increased PPARδ reporter activity induced by PUA in vitro in IEC and macrophages. As CLA, PUA up-regulated colonic keratinocyte growth factor levels in the present study. Since PPARδ plays an important role in re-epithelialisation in mouse epidermis, the up-regulated colonic keratinocyte growth factor may be indicative of a PPARδ-mediated re-epithelialisation of the gut mucosa.

In contrast to PPARδ and its responsive genes, colonic levels of PPARγ, α and their responsive genes remained unchanged. Nonetheless, since PUA transactivates PPARγ in 3T3-L1 pre-adipocytes and given the abrogation of the effect of PUA that we observed in PPARγ; IL-10 DK mice, this isoform was also investigated as a putative target for PUA. PPARγ suppresses inflammation by antagonising NF-κB, STAT and AP-1, favouring the nucleocytoplasmic shuttling of the activated p65 subunit of NF-κB, and SUMOylation of PPARγ results in a stable repressed state of NF-κB. Thus, the down-regulation of TNF-α in colons of PUA-fed mice and

---

Fig. 4. Effect of dietary punicic acid (PUA) supplementation on experimental inflammatory bowel disease during a 7d challenge with dextran sodium sulphate. (A) Disease activity indices, (B) gross lesions in C57BL/6J wild-type (WT) and PPARγ null mice fed either a control or a PUA-supplemented diet. Values are means, with standard errors represented by vertical bars. Mean values with unlike letters were significantly different (P<0·05, n 10). – – –, WT control; – - –, WT PUA; ——, PPARδ control; . . . ., PPARδ PUA.

Fig. 5. Effect of dietary punicic acid (PUA) supplementation on experimental inflammatory bowel disease during a 7d challenge with dextran sodium sulphate. (A) Disease activity indices, (B) gross lesions in Villin-Cre–C57BL/6J wild-type (WT) and intestinal epithelial cell-specific PPARγ null (Villin-Cre−) mice fed either a control diet or a PUA-supplemented diet. Values are means, with standard errors represented by vertical bars. Mean values with unlike letters were significantly different (P<0·05, n 10). – – –, WT control; – - –, WT PUA; ——, VillinCre− control; . . . ., VillinCre− PUA.
Moreover, PPARγ macrophages (55). Based on this background, to further characterise the putative roles of PPARγ and δ have been shown to suppress M1 classically activated or pro-inflammatory macrophage activation and favour M2 alternatively activated or anti-inflammatory macrophage differentiation (52–54).

In addition, activation of PPARγ and δ has been shown to exert overlapping anti-inflammatory effects in lipopolysaccharide-stimulated macrophages (55). Based on this background, to further characterise the putative roles of PPARγ and δ as targets for PUA, we determined whether the deletion of these genes impaired or abrogated its ability to ameliorate experimental IBD. Our data demonstrate that both PPARγ and δ are required for PUA-mediated protection from DSS colitis. Additionally, PPARγ was also required for PUA-mediated protection from IL-10-induced pan-enteritis since the preventive effect of PUA was abrogated in PPARγ null (Lysozyme M-Cre+ ) mice. However, we could not test the role of PPARδ in spontaneous pan-enteritis in IL-10 knockout mice since PPARδ; IL-10 DK mice did not survive beyond the embryonic stages.

At the cellular level, the deletion of PPARγ in macrophages completely abrogated the beneficial effect of PUA, whereas its deletion in IEC or the whole-body deletion of PPARδ impaired, but did not completely abrogate, the anti-inflammatory activity of PUA in the gut. Together, these data indicate that PUA ameliorates experimental IBD by down-modulating inflammation in mucosal immune and epithelial cells through PPARγ- and δ-dependent mechanisms. In support of this assertion, we provide in vitro evidence demonstrating that PUA treatment suppressed the TNF-α- and MCP-1-producing abilities of wild-type M1 classically activated macrophages, but it failed to exert these suppressive effects in PPARγ or δ null macrophages. Furthermore, PUA intake increased the peripheral blood regulatory T-cell compartment in wild-type mice but not in PPARγ or δ null mouse strains. These findings are in line with a PPARγ-dependent up-regulation of Foxp3 in regulatory T-cells treated with PUA (data not shown). Of note, regulatory T-cells mediate protection from experimental colitis through PPARγ-dependent mechanisms (28,34). Since colonic PPARγ was required for some of the anti-inflammatory effects of PUA in vivo, but it did not activate PPARγ reporter activity

**Fig. 6.** Effect of dietary punicic acid (PUA) supplementation on experimental inflammatory bowel disease during a 7 d challenge with dextran sodium sulphate. (A) Disease activity indices, (B) gross lesions in Lysozyme M-Cre+ -C57BL/6J wild-type (WT) and macrophage-specific PPARγ null (Lysozyme M-Cre+ ) mice fed either a control diet or a PUA-supplemented diet. Values are means, with standard errors represented by vertical bars. a,b,c Mean values with unlike letters were significantly different among the treatments (P<0·05, n 10). – – –, WT control; – - –, WT PUA; ——, Lysozyme M Cre+ control; ———, Lysozyme M Cre+ PUA.

**Fig. 7.** Dietary punicic acid modulates the percentages of regulatory T-cells in the peripheral blood of C57BL/6J wild-type (WT) mice but not in PPARδ null, macrophage-specific PPARγ null (Lysozyme M (LysM)-Cre+ ), intestinal epithelial cell-specific PPARγ null (Villin-Cre+ (VC+)) mice with dextran sodium sulphate (DSS) colitis. Values are means, with standard errors represented by vertical bars. a,b,c Mean values with unlike letters were significantly different among the treatments (P<0·05, n 10). PPARδKO, PPAR double knockout; WT no DSS, WT without DSS.
directly, further studies are required to determine whether IEC and/or immune cells produced endogenous PPARδ agonists in response to PUA-mediated activation of PPARs. In conclusion, PUA prevented experimental IBD through a mechanism requiring adequate expression of PPARγ and δ in immune cells and IEC in the colonic mucosa.

Acknowledgements

The present study was supported by funds from Lipid Nutrition BV. J. B.-R., R. H., Z. E. J., M. O.’ S. and A. W. C. E. designed the experiments, interpreted the results, wrote the manuscript and managed the project. M. D., M. C., C. V. and A. C. conducted the animal studies. M. C. and C. V. conducted the in vitro studies. J. B.-R. filed a patent related to PUA. R. H., Z. E. J., M. O.’ S., A. W. C. E., M. D., M. C., C. V. and A. C. declare that they have no conflict of interests.

References
